Literature DB >> 11167284

Hemostatic effects of SF6 after diabetic vitrectomy for vitreous hemorrhage.

C N Koutsandrea1, M N Apostolopoulos, D Z Chatzoulis, E A Parikakis, G P Theodossiadis.   

Abstract

PURPOSE: To investigate the hemostatic effects of SF6 gas in preventing postoperative vitreous hemorrhage in diabetic vitrectomy.
METHODS: A prospective, randomized study of 33 diabetic eyes with vitreous hemorrhage, treated by vitrectomy. In 17 of our cases SF6 20% was injected into the eye at the end of the operation, while in 16 cases BSS remained in the vitreous cavity.
RESULTS: The incidence of vitreous hemorrhage recurrence was 17.6% for the SF6 group and 12.5% for the BSS group (statistically not significant). Progression of lens opacities was observed in 23.5% of the SF6 group, and in 18.8% of the BSS group (statistically not significant, with a higher incidence in the SF6 group).
CONCLUSIONS: SF6 gas did not show hemostatic effects in the cases studied. Furthermore, it may have contributed to cataract progression. Therefore we suggest that the use of SF6 is not recommended as a treatment modality in preventing new vitreous hemorrhage after diabetic vitrectomy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11167284     DOI: 10.1034/j.1600-0420.2001.079001034.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  8 in total

1.  Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study.

Authors:  Dong Ho Park; Jae Pil Shin; Si Yeol Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-12-12       Impact factor: 3.117

2.  Management of postvitrectomy diabetic vitreous hemorrhage with volume homeostatic fluid-fluid exchanger.

Authors:  Wen-Chuan Wu; Jen-Yu Chen; Ya-Chi Chen; Yo-Chen Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-07       Impact factor: 3.117

3.  Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin).

Authors:  Wayne R Lo; Stephen J Kim; Thomas M Aaberg; Christopher Bergstrom; Sunil K Srivastava; Jiong Yan; Daniel F Martin; G Baker Hubbard
Journal:  Retina       Date:  2009 Jul-Aug       Impact factor: 4.256

4.  Sulfur Hexafluoride 20% versus Lactated Ringer's Solution for Prevention of Early Postoperative Vitreous Hemorrhage after Diabetic Vitrectomy.

Authors:  Fereydoun Farrahi; Mostafa Feghhi; Biuk Bagherzadeh; Mahmood Latifi
Journal:  J Ophthalmic Vis Res       Date:  2010-04

5.  The adjunctive use of pre-operative intravitreal bevacizumab in the setting of proliferative diabetic retinopathy.

Authors:  Abdullah Al-Kharashi; Tural Galbinur; Efrem D Mandelcorn; Rajeev H Muni; Mir Nabavi; Peter J Kertes
Journal:  Saudi J Ophthalmol       Date:  2016-10-29

6.  The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study.

Authors:  Tingting Jiang; Junxiang Gu; Peijun Zhang; Wenwen Chen; Qing Chang
Journal:  BMC Ophthalmol       Date:  2020-02-03       Impact factor: 2.209

Review 7.  Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.

Authors:  Jonathan M Smith; David H W Steel
Journal:  Cochrane Database Syst Rev       Date:  2015-08-07

8.  Risk factors for requirement of filtration surgery after vitrectomy in patients with proliferative diabetic retinopathy.

Authors:  Masashi Sakamoto; Ryuya Hashimoto; Izumi Yoshida; Takatoshi Maeno
Journal:  Clin Ophthalmol       Date:  2018-04-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.